Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer
Status:
Terminated
Trial end date:
2011-02-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the
tumor and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Giving stereotactic body radiation therapy
together with gemcitabine hydrochloride may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects of stereotactic body radiation
therapy when given with or without gemcitabine hydrochloride in treating patients with
pancreatic cancer that can be removed by surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Simmons Cancer Center University of Texas Southwestern Medical Center